Technical Analysis for VRCA - Verrica Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 8.96 -0.55% -0.05
VRCA closed down 0.55 percent on Tuesday, August 20, 2019, on 28 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VRCA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -0.55%
NR7 Range Contraction -0.55%
Inside Day Range Contraction -0.55%
Wide Bands Range Expansion -0.55%
Oversold Stochastic Weakness -0.55%
Slingshot Bearish Bearish Swing Setup -2.50%
Wide Bands Range Expansion -2.50%
Oversold Stochastic Weakness -2.50%

Older signals for VRCA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Health Pharmaceutical Pharmaceutical Industry Medication Pharmaceutical Products Clinical Trial Common Warts Skin Diseases Treatment Of Skin Diseases
Is VRCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 7 Verrica Pharmaceuticals EPS beats by $0.06
Jul 4 Verrica's Mid-Stage Results For Common Warts Put It In A Sweet Spot With FDA Meeting
Jun 27 Mid-stage study underway for Verrica's VP-102 for genital warts
Jun 27 Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
Jun 27 The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Jun 26 OFG, VRCA, ACRS and PIR among after hour movers
Jun 26 Aclaris, KB Homes, Pier 1 Moving In Wednesday's After-Hours Session
Jun 26 Verrica's VP-102 shows positive effect in mid-stage study; shares up 6% after hours
Jun 26 Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
May 28 What Type Of Shareholder Owns Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA)?
See more VRCA news...
Indicators
Indicator Value
52 Week High 18.575
52 Week Low 6.44
Average Volume 51,691
200-Day Moving Average 10.6195
50-Day Moving Average 10.3312
20-Day Moving Average 10.3305
10-Day Moving Average 9.557
Average True Range 0.8638
ADX 19.17
+DI 17.3628
-DI 24.318
Chandelier Exit (Long, 3 ATRs ) 9.9686
Chandelier Exit (Short, 3 ATRs ) 10.981400000000001
Upper Bollinger Band 12.4829
Lower Bollinger Band 8.1781
Percent B (%b) 0.18
BandWidth 41.670781
MACD Line -0.4342
MACD Signal Line -0.2181
MACD Histogram -0.2161
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.04
Resistance 3 (R3) 9.97 9.54 9.86
Resistance 2 (R2) 9.54 9.26 9.58 9.80
Resistance 1 (R1) 9.25 9.10 9.04 9.32 9.74
Pivot Point 8.82 8.82 8.71 8.86 8.82
Support 1 (S1) 8.53 8.54 8.32 8.60 8.18
Support 2 (S2) 8.10 8.38 8.14 8.12
Support 3 (S3) 7.81 8.10 8.06
Support 4 (S4) 7.88